KYTX NASDAQ

Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.07 (down 99%), Kyverna Therapeutics, Inc. would be worth roughly what it owes.
Total debt $33.0M against a stock market value of $325.9M.
Distance to default 3.36 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $12.4M (short-term plus half of long-term), stock volatility 91.3%; Altman Z'' -3.38. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.